Prof. Yang Mengsu (Michael) obtained his B.Sc. from Xiamen University, China, Ph.D. from University of Toronto, Canada, and postdoctoral training in the Scripps Research Institute in USA. He is currently Yeung Kin-Man Chair Professor of Biomedical Sciences, in City University of Hong Kong, and Director of Biotech and Health Center in City University’s Shenzhen Research Institute. The research interest of Yang’s group focuses on the development of biochip technology and nanotechnology for molecular diagnostics and therapeutic applications. Prof. Yang has published over 280 peer-reviewed papers, received 23 USA/China patents, and trained 35 Ph.D. graduates and numerous postdoctoral fellows in his laboratory. He has been awarded the Chunhui Scholar Award by the Ministry of Education in China in 2003, the K. C. Wong Foundation Award in 2004, the Shenzhen Science and Technology Innovation Award in 2006, the Hong Kong Technological Achievement Grand Award in 2007, the Natural Science Award by the Ministry of Education in 2015, and the Wuxi PharmaTech Life Science and Chemistry Award in 2016. Prof. Yang also serves as a member of the Innovation and Technology Fund and the Healthcare and Medical Research Fund, Vice Chairman of Hong Kong Biotech Organization, Director of Guangdong-Hong Kong-Macau Greater Bay Area Biotech Federation, and Mentor of Hong Kong X-Tech Platform.
Liquid biopsy holds the potential to obtain molecular and/or cellular information from blood samples from primary or metastatic lesions that are inoperable or difficult to access by tissue/needle biopsy. It provides great opportunities to closely monitor the response of cancer patients to therapy and facilitate treatment decisions. Over the last decade, circulating tumor cells (CTCs) have received growing attention in the field of liquid biopsy, as increasing amount of data has shown the prognostic and predictive value of CTCs in various cancers. Technologies for CTC isolation have been designed to capture CTCs by using cell surface markers or by exploiting the biophysical
Properties of CTCs. In addition to CTC counting, analytical assays for EMT phenotyping of CTC, measuring CTC proteins such as HER2 andPD-L1, detecting target mutations in CTC, and whole genome sequencing of isolated CTC, will provide new opportunities for biomedical research and offer essential clinical information for precision oncology.